Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 May;25(3):269-75.

Variations in response to citalopram in men and women with alcohol dependence

Affiliations
Clinical Trial

Variations in response to citalopram in men and women with alcohol dependence

C A Naranjo et al. J Psychiatry Neurosci. 2000 May.

Abstract

Objective: To examine the differential effects of citalopram on alcohol consumption in nondepressed women and men with mild to moderate alcohol dependence.

Design: Prospective, placebo-controlled study.

Participants: Sixty-one subjects (34 men and 27 women).

Interventions: After a 2-week baseline, subjects were randomly assigned to 12 weeks of citalopram (40 mg per day) (n = 15 women, 16 men) or placebo (n = 12 women, 18 men). All received brief standard psychosocial interventions.

Outcome measures: Alcohol Dependence Scale, Montgomery-Asberg Depression Scale, Michigan Alcohol Screening Test, State-Trait Anxiety Inventory and daily alcohol intake.

Results: Pretreatment sex differences were evident in alcohol consumption, alcohol dependence, alcohol-related problems and on anxiety and depression measures. After treatment, analyses of covariance with depression and anxiety scores as covariates revealed a differential benefit of citalopram for men. Men receiving citalopram reduced average drinks per day by 44%, whereas women exhibited a 27% decrease (p < 0.05).

Conclusions: Men may benefit more than women from citalopram in the treatment of alcohol dependence. These findings highlight the importance of examining sex as a significant variable in evaluating response to pharmacotherapy.

PubMed Disclaimer

References

    1. Neurosci Lett. 1996 Feb 2;204(1-2):25-8 - PubMed
    1. J Nerv Ment Dis. 1996 Oct;184(10):616-22 - PubMed
    1. J Stud Alcohol. 1997 Jan;58(1):7-29 - PubMed
    1. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Nov;20(8):1315-23 - PubMed
    1. Clin Pharmacokinet. 1997;32 Suppl 1:1-21 - PubMed

Publication types